FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).Looking up:…
Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors
The major provider of gene-edited lab rodents gets the nod for a Hong Kong listing after abandoning a plan to float shares on Shanghai’s STAR Market Key Takeaways: Gene-edited lab…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
